Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics aimed at treating various cancers. The operating income ratio is 0.00 indicating the company's operational profitability margin. Its lead product candidate, ZN-c3, is a WEE1 inhibitor currently undergoing multiple clinical trials, including a Phase 2 study for advanced solid tumors and a Phase 1/2 trial as a monotherapy and in combination with chemotherapy for platinum-resistant ovarian cancer. Additionally, ZN-c3 is being evaluated in a Phase 2 monotherapy trial for a tumor-agnostic predictive biomarker. Another significant candidate is ZN-c5, an oral selective estrogen receptor degrader, which is in a Phase 1/2 clinical trial for advanced ER-positive, HER2-negative breast cancer. The earnings per share (EPS) is reported at -$4.47 indicating the company's profitability on a per-share basis. Furthermore, Zentalis is advancing ZN-d5, a selective BCL-2 inhibitor currently in a Phase 1 trial for non-Hodgkin's lymphoma and acute myelogenous leukemia, as well as ZN-e4, an irreversible inhibitor of mutant EGFR in a Phase 1/2 trial for advanced non-small cell lung cancer. The operating expenses amount to $252,552,000.00 encompassing various operational costs incurred. The cost of revenue for the company is $1,389,000.00 showcasing its production and operational expenditures. The company's stock is identified with the symbol 'ZNTL' in the market. Currently, the stock is affordable at $1.64 making it suitable for budget-conscious investors. With a high average trading volume of 1,778,171.00 the stock signals strong liquidity and an active trading environment. Zentalis Pharmaceuticals operates within the Biotechnology industry, which contributes significantly to the overall market landscape. With a market capitalization of $114,180,285.00 the company is classified as a small-cap player, presenting unique growth opportunities. It belongs to the Healthcare sector, driving innovation and growth through its promising pipeline of therapeutic candidates and strategic partnerships with organizations including Recurium IP Holdings, LLC, and Pfizer, Inc.